The purpose of the study is to evaluate the effectiveness and safety of adding Privosegtor to standard therapy for individuals with Optic Neuritis.

Participants receive the infusion at the start of the study and are followed for three months, with clinic visits to check vision and safety. Vision is tested using low contrast visual acuity, a measure of how well a person can see faint patterns, and the eye’s structure is examined with optical coherence tomography, a non‑invasive scan that measures retinal layer thickness. A blood test for serum neurofilament light chain is performed to assess nerve damage, and questionnaires evaluate the impact of vision changes on daily life. Changes in these assessments are compared between the drug and placebo groups.

The main goal of the trial is to find out whether the medication can slow the increase in the size of the damaged areas of the retina. The study is designed so that participants are randomly assigned to receive either the active drug or the placebo, and neither the participants nor the study staff will know which treatment is given. The trial will last about two years, with regular clinic visits for assessments.

During the study, participants will take one capsule each day and attend scheduled visits where several eye tests are performed. A special camera called FAF will take pictures that highlight unhealthy retinal tissue, while an imaging technique known as OCT will create cross‑sectional views of the eye’s layers. Vision will be measured using a standard eye chart (ETDRS) to determine BCVA, and low‑light reading ability will also be checked. Reading speed will be evaluated with two tests, IReST and MNRead. Sensitivity of the retina will be mapped with microperimetry, and participants will complete questionnaires such as the NEI-VFQ-25 to report how the condition affects daily activities.

The purpose of the study is to determine whether the new medicine works as well as the existing one. Participants will receive a series of these eye injections over several months and will have regular eye examinations. Vision will be checked using a test called BCVA, measured with an ETDRS chart, which is a standardized eye chart used to assess how well a person can read letters. Doctors will also look for signs of fluid inside the retina, called IRF and SRF, and will measure the size of the abnormal blood‑vessel area, known as CNV, using imaging methods such as FA and SD-OCT. Safety will be monitored throughout the study, including checking for any immune reactions called ADAs.

The purpose of the study is to determine if the eye drops allow the interval between injections to be extended. Vision will be measured with a standardized eye chart called the ETDRS chart, which provides a precise reading of visual sharpness. The health of the retina will be monitored using OCT, a non‑invasive scan that creates detailed cross‑section images of the back of the eye. Safety checks will include measuring the eye’s internal pressure (IntraOcular Pressure), assessing tear film stability with the Tear Break-Up Time test, and rating any irritation on a Visual Analog Scale, a simple line where participants indicate how uncomfortable they feel.

Participants will use the assigned eye drops daily for about nine months and will attend regular clinic visits for eye examinations and possible adjustment of injection timing. The study is double‑blind, meaning neither the participants nor the doctors know which drops are being used, and data on injection frequency, visual acuity, retinal thickness, and safety outcomes will be collected at the end of the treatment period.

Participants will receive several injections over a period of time and will attend regular visits where doctors will check the eyes for any side effects. During these visits the eyes will be examined with tools such as a slit lamp biomicroscopy and a dilated ophthalmoscopy to look at the front and back of the eye, and the pressure inside the eye (intraocular pressure) will be measured. Images of the retina will be taken using spectral domain-optical coherence tomography, color fundus photography, and tests of how well the person can see details and contrasts, including a measurement of contrast sensitivity function and an assessment of best corrected visual acuity.

Throughout the study doctors will record any eye problems or other health events, watch how the retina changes, and note any differences in vision quality. The information gathered will help determine if the drug can be used safely and if it shows any early signs of helping to preserve vision in this condition.

The aim is to find out whether the nasal dose of the study drug reduces the pain measured by the Premature Infant Pain Profile‑Revised during the first 30 seconds after the eye speculum is placed. Infants are randomly assigned to receive either the study drug or the placebo, then undergo the standard eye screening while pain scores and basic vital signs are recorded. After the exam the infants continue to be observed for a short period to monitor any breathing changes, oxygen needs, crying, sleep, or other reactions before returning to regular care.

The purpose of the trial is to determine whether the new drug works at least as well as the existing treatment in preserving or improving vision. Vision will be assessed using a standard test called Best-Corrected Visual Acuity, which measures how many letters a person can read on an eye chart, reported in ETDRS letters.

Participants will receive a series of eye injections over roughly one year, with regular visits to check eye health, vision scores, and any side effects. The study is designed so that neither the participants nor the doctors know which medication is being given at each visit.

Children in the study receive eye drops in a single-dose container and are followed over several months. During the study, eye health, vision, eye comfort, and possible side effects are checked at different visits and by phone calls. The study also looks at changes in the length of the eye, which can increase as myopia gets worse, as well as other eye findings such as redness, eye surface irritation, eye pressure, and the condition of the cornea, which is the clear front part of the eye.

The trial compares T10430 with placebo to learn more about safety and possible benefit. The treatment is given to both eyes, and the study follows participants for about one year.

This is an open-label study, which means the treatment is known to the study team and the participants. People in the study will continue receiving AMG 732 for a period of time and will have regular study visits over the course of the trial. During these visits, the study team will check for any side effects and follow changes in the eye condition. The study is planned to run for a number of years.

People in the study are assigned by chance to one of the eye drop groups. The study lasts for several weeks, and the eye is checked during treatment and again afterward to see whether healing has been maintained. The main focus is whether the damaged eye surface closes and stays healed over time.

The study will compare FWY003 with placebo in people with this eye condition. It is a randomized study, which means the treatment is assigned by chance, and double masked, which means neither the participants nor the study team know who receives FWY003 or placebo during the study. Over time, the study follows changes in the damaged area in the eye and also watches for side effects and other health changes. The study lasts for many months and includes regular visits during which eye health and general well-being are reviewed.

Both medicines are given as intravitreal injections, which means they are injected into the eye. In the study, treatment is given over time, and the eye is checked during the study visits to see how the condition changes and whether more than one injection is needed. The purpose of the study is to find out whether faricimab can help improve vision and control the eye disease as well as or better than ranibizumab.

The purpose of the study is to evaluate the safety and effectiveness of AAVB-039. The investigation is divided into two parts. The first part focuses on finding the safest and most appropriate amount of the medicine to use. The second part examines how well the treatment works at that specific dose over time.

Participants in the study will be monitored to observe any changes in their vision and the health of their eyes. This includes checking the ellipsoid zone, which is a specific layer of cells in the retina that is important for clear vision, and the macula, the part of the eye responsible for detailed central sight. The study will track these changes over several years to understand the long-term impact of the treatment.

Participants in this long-term study will take the medication over a period of three years. During this time, the effects of the treatment on the body and the eyes will be monitored to ensure it is safe for continued use.

Participants in the study will be assigned to receive either the test medication or the comparison medication. The process involves monitoring changes in best corrected visual acuity, which refers to how clearly a person can see when wearing glasses or contact lenses. The study will observe how these treatments affect the thickness of the retina and how frequently eye treatments are required over a set period of time.

During the study, participants will receive the medication and will be monitored for any side effects or how their bodies react to the treatment. The process involves checking for anti-drug antibodies, which are substances the body might create to fight against a medication. Researchers will also look at various aspects of eye health and how the medication moves through the body.

During the study, participants will receive either the new implant or the standard injection. The process involves monitoring changes in best corrected visual acuity, which refers to the clearest vision a person can achieve with glasses or contact lenses. Researchers will also observe changes in the thickness of the retina and how well participants can read letters on an eye chart over a period of time. The study will track how often additional treatments are required and how the swelling in the eye responds to the different options provided.

During the study, participants will be assigned to one of two groups to receive either the new generic combination or the comparison medication. Both treatments are administered as eye drops. The process involves monitoring the pressure within the eye over a period of time to see how well each medicine works to lower these levels.

Participants in the study will receive either ADX-038 or a placebo through a subcutaneous injection, which is a method of delivering medication into the fatty tissue just beneath the skin. The study will monitor changes in the size of the affected areas and the health of the photoreceptors, which are the specialized cells in the eye that respond to light. This process involves using advanced imaging techniques such as optical coherence tomography, a non-invasive way to take cross-section pictures of the retina, and fundus autofluorescence, a specialized eye imaging test that helps visualize the health of the retinal layers.

Participants in this research will be given upadacitinib, which is an oral medication taken in the form of a prolonged-release tablet. This type of pill is designed to release the medicine slowly into the body over time. The study will follow the participants over a period of 52 weeks to observe how frequently episodes of eye inflammation occur while taking the medication.

During the study, participants will receive either AVT29 or a high dose of Eylea. The medical team will monitor changes in best-corrected visual acuity, which refers to the clearest vision possible with glasses or contact lenses. Additionally, the study will look at changes in central subfield thickness, a measurement of how much the middle part of the retina has thickened due to swelling, and the presence of intraretinal fluid, which is liquid trapped inside the layers of the retina. Regular check-ups will also be performed to monitor intraocular pressure, the fluid pressure inside the eye, and other general health factors to ensure safety throughout the process.

During the study, participants will take 2 grams of NICOBION, which is a film-coated tablet, every day for one year. Throughout this period, various aspects of vision and eye health will be monitored. This includes checking how clearly people can see at different distances and assessing the health of the eye layers through optical coherence tomography, a non-invasive imaging test that uses light to take cross-section pictures of the retina. Blood tests may also be used to check the levels of the vitamin in the body and to monitor liver function.

The treatment being tested is an anti-CD3 monoclonal antibody called REGN7041. This medication is provided as a solution for injection and is administered via intravitreal use, which means the medicine is injected directly into the jelly-like substance inside the eye. Participants may receive either a single dose or repeated doses of this substance during the course of the study.

During the study, participants will use different types of eye drops. The research will monitor several aspects of eye health, such as conjunctival hyperaemia, which is an increase in blood flow that makes the white part of the eye look red, and ocular pain or discomfort. The study also looks at central macular thickness, which refers to the thickness of the part of the retina responsible for sharp, central vision, using a specialized imaging method called optical coherence tomography. Other factors monitored include intraocular pressure, which is the fluid pressure inside the eye, and best corrected visual acuity, which is the clearest vision possible with the help of glasses or contact lenses.

Participants in the study will receive two initial high doses of the medication. Following these starting doses, the study will observe the effects on the eye over several weeks. This includes monitoring changes in visual acuity, which is the clarity or sharpness of vision, and checking for any fluid in the macula, the central part of the retina responsible for detailed vision. Specialized imaging such as optical coherence tomography, a non-invasive way to take cross-section pictures of the retina, may be used to look at the thickness of the retinal layers and the presence of fluid.

Participants first receive several doses of itraconazole taken by mouth. After this period, they take one dose of BI 1815368, also taken by mouth. Blood samples are collected at various times to measure the amount of the experimental drug that is present. The same participants later take a single dose of BI 1815368 without any itraconazole, and blood is sampled in the same way. By comparing the two situations, researchers can see how itraconazole influences the level of the experimental drug in the blood.

The purpose of this study is to find out whether the antisense oligonucleotide eye drops work effectively in treating the abnormal blood vessels in the cornea when used together with the corneal crosslinking procedure. During the study, participants will receive either the active eye drops or placebo eye drops along with the other standard medications and will undergo the crosslinking procedure. The study will measure changes in the area of the cornea covered by abnormal blood vessels by taking standardized photographs of the eye using a special microscope called a slit lamp. The treatment period will last for several weeks, and participants will be followed for additional time to see how well the treatment works.

Throughout the study, various measurements will be taken to assess how well participants can see, including tests of visual sharpness both in normal conditions and with glare, which is bright light that can make seeing more difficult. The study will also evaluate how the condition and treatment affect quality of life related to vision and any eye pain experienced by participants. Other measurements will include eye pressure, the health of the eye surface, how well the cornea can sense touch, the thickness of the cornea, and detailed measurements of the blood vessels including their thickness and length. Safety will be monitored by examining the retina, which is the light-sensitive tissue at the back of the eye, and by tracking whether participants still need a corneal transplant after treatment.

The purpose of the study is to compare how well K1-70 works compared to placebo in reducing the bulging of the eyes in people with active thyroid eye disease. The main focus is to see if K1-70 can help decrease how much the eyes protrude forward by at least a certain amount after 24 weeks of treatment. The study will also look at other aspects of the disease, such as changes in eye muscle inflammation seen on MRI scans, improvements in quality of life, changes in disease activity scores, improvements in double vision, and changes in the volume of tissue behind the eye. Additionally, the study will monitor safety by checking for any side effects, measuring vital signs, performing heart tests with an ECG, conducting laboratory tests, and examining the eyes and overall health of participants.

Participants will receive K1-70 or placebo once every 6 weeks for a total of 24 weeks. The study will measure various outcomes throughout the treatment period and will continue to follow participants after the treatment is completed. The medication will be given at a dose of up to 100 milligrams per infusion, with a maximum total dose of 800 milligrams over the entire treatment period of 48 weeks. The study will also measure the levels of the medication in the blood over time and check for any immune responses to the treatment.

The purpose of the study is to evaluate how well teprotumumab works compared to placebo in reducing eye bulging in people with this condition, and to assess its safety and how well it is tolerated. The study will measure whether the eyes move back into a more normal position by at least 2 millimeters without the other eye getting worse. The study will also look at other aspects of the disease, including signs of inflammation, double vision, and how the condition affects quality of life.

Participants in this study will be randomly assigned to receive either teprotumumab or placebo through injections under the skin. The study will follow participants over a period of time to monitor changes in eye bulging, inflammation scores, double vision, and overall well-being. Participants must have active disease with significant eye bulging and symptoms that started within 15 months before joining the study. Their thyroid hormone levels should be controlled or only mildly abnormal during the study.

The purpose of this study is to determine how many patients have complete clearing of the subretinal hyperreflective material after 16 weeks of treatment with faricimab. The study will use special imaging techniques called multimodal imaging to examine the eye and assess changes in this abnormal tissue. Multimodal imaging means using different types of eye scans and photographs to get detailed pictures of the structures inside the eye. This helps doctors see whether the treatment is working to remove the abnormal material from beneath the retina.

During the study, patients will receive faricimab injections into the affected eye according to the approved treatment schedule. The study will monitor patients over time to see if the abnormal tissue resolves and to evaluate how well the treatment works. The medication will be given to patients who have not previously received treatment for this condition, meaning their eyes are treatment-naive. The total treatment period for each patient will last up to three years, though the main assessment of whether the abnormal tissue has cleared will happen at week 16.

The purpose of this study is to find out how many injections people need after receiving the gene therapy compared to those who continue getting regular injections of ranibizumab, and to see how well the gene therapy works in preserving vision over time in a setting that is similar to everyday medical practice. The study will also look at the safety of the gene therapy and measure any side effects that may occur in the treated eye or the other eye. Additionally, the study will check for changes in areas of damage in the central part of the retina.

People taking part in the study will be randomly assigned to receive either the gene therapy or ranibizumab. Those who receive the gene therapy will have it injected under the retina during a surgical procedure, while those in the comparison group will receive ranibizumab injections into the eye as needed based on how their condition responds. During the first year, people will be monitored closely and receive additional injections if needed according to specific guidelines. After the first year, the treatment schedule will follow a more flexible approach that reflects how treatment is typically managed in regular clinics. The study will last for several years to see how well vision is maintained over the long term.

The purpose of this study is to evaluate how well the injection of these donor-derived cells into the area under the conjunctiva works in preserving the eyeball six months after the first injection in patients who have suffered a severe chemical burn to the eye surface in the recent past. The study will focus on patients whose chemical burn occurred within fifteen days before joining the study and whose burn is classified as very severe, affecting the entire border area around the cornea and the conjunctiva.

During the study, patients will receive the cell treatment as an injection under the membrane covering the eye. The study team will monitor the treated eye over time to check whether the cornea, which is the clear front surface of the eye, develops a hole or perforation. They will also examine other aspects of eye health, including the extent of damage to the limbal area where stem cells normally live, the degree of scarring and blood vessel growth on the cornea, signs of inflammation in the eye surface tissues, visual ability, and detailed images of the front part of the eye using specialized scanning technology. Information about any additional treatments needed and any unwanted effects will be collected from medical records and patient assessments throughout the study period.

The purpose of the study is to find out if atorvastatin can prevent the development of active Graves ophthalmopathy in patients who have just been diagnosed with Graves’ disease. Participants will take atorvastatin tablets by mouth for a period of 12 months. The maximum daily dose will be 40 milligrams. During the study, patients will be monitored at several time points over 18 months to check if they develop eye problems and to measure the activity level of any eye inflammation using a scoring system. The study will also look at how the treatment affects quality of life and measure certain antibodies in the blood that are related to the disease.

Throughout the study period, researchers will collect information about whether patients need additional treatments for eye problems, such as corticosteroids or other medications. Blood samples will be analyzed to look for biological markers that might help predict who will respond well to the treatment. The study will also examine genetic differences between people who respond to atorvastatin and those who do not. Patients will complete questionnaires about their quality of life at the beginning of the study, after 12 months, and after 18 months to see how the treatment affects their daily living and well-being.

The purpose of this study is to find out how well two different dose levels of GS010 work in improving vision and how the retina, which is the light-sensitive layer at the back of the eye, functions after treatment. The study will look at changes in visual sharpness, which is measured using something called best corrected visual acuity, and will compare the results between patients receiving a higher dose and those receiving a lower dose. Patients in this study will receive injections in both eyes and will be followed for one and a half years after treatment to see how their vision changes over time.

During the study, patients will attend regular visits where their vision will be tested and their eyes will be examined to check for any side effects or problems. The study will also monitor for specific eye-related issues such as inflammation inside the eye and increases in eye pressure, as well as any other side effects that may occur. Images of the eye will be taken using a technique called optical coherence tomography to help doctors assess the condition of the retina and optic nerve throughout the study period.

The purpose of this study is to test whether Olisens eye drops can stop or reduce the abnormal blood vessel growth in the cornea of people with Aniridia-Associated Keratopathy. The main goal is to measure if the treatment can decrease the area of the cornea that is covered by these unwanted blood vessels. During the study, participants will receive the eye drop treatment for up to 12 weeks, with a maximum daily dose of 0.52 milligrams. The study will track changes in the blood vessel coverage on the cornea using special photographs taken with a device called a slit lamp, which allows doctors to examine the eye in detail.

Throughout the study, several other measurements will be taken to understand how the treatment affects the eyes and the quality of life of participants. These include checking how well participants can see using special eye charts, measuring the pressure inside the eye, examining the surface of the eye for any damage, testing how sensitive the cornea is to touch, and measuring the thickness of the cornea. The study will also look at the characteristics of the blood vessels themselves, such as their thickness and length, and whether they shrink or come back after treatment. Additionally, participants will complete questionnaires about their vision-related quality of life and any eye pain they experience. The back part of the eye called the retina will also be examined to check for any unwanted effects of the treatment.

The purpose of the study is to see if tildrakizumab can improve the eye problems that remain after Lyell syndrome. The main focus is on measuring how long the tear film stays stable on the eye surface before breaking up, which is an important sign of eye surface health. A longer time means better moisture and less irritation. The study will also look at how patients feel about their eye symptoms and how these problems affect their quality of life and ability to see clearly.

During the study, participants will receive the treatment and attend follow-up visits where doctors will check their eyes and measure changes in tear film stability. Safety will be monitored throughout the study, and participants will be asked about how well they tolerate the treatment and any changes in their symptoms. The study is expected to run from early 2026 until mid-2027.

People taking part in the study will be randomly assigned to receive either one injection of the experimental treatment or regular injections of the approved medication. Before starting the main part of the study, participants will receive one injection of the approved medication to make sure their condition responds to this type of treatment. During the study, doctors will measure vision using an eye chart and will take images of the eye to see how the condition is changing. The main measurement will be the change in vision after one year of treatment. Doctors will also track how many additional injections are needed and whether the experimental treatment can reduce the need for repeated injections compared to the standard treatment.

The study will last several years and will continue to follow participants to see how long the effects of the treatments last. Throughout the study, participants will have regular visits where their vision will be tested and their eyes will be examined. The study aims to determine whether the single injection of gene therapy can provide lasting benefits and reduce the treatment burden for people with this eye condition.

The purpose of this study is to confirm whether DFL24498 eye drop solution is effective in reducing eye itching and improving other signs of the condition in adults with Atopic Keratoconjunctivitis after six weeks of treatment. The study will measure how much the itching improves, as well as changes in damage to the clear front part of the eye, which is called the cornea, and redness of the white part of the eye, which is called the conjunctiva. The main goal is to see if the investigational eye drops can help relieve the uncomfortable symptoms that people with this condition experience.

During the study, participants will be randomly assigned to receive either DFL24498 eye drops or placebo eye drops, and neither the participants nor the doctors will know which treatment is being given. The treatment will continue for twelve weeks, with regular visits to check how well the eyes are responding and to monitor for any side effects. At these visits, doctors will examine the eyes, ask about symptoms, and assess the overall condition using various measurement scales. The study will track changes in itching levels, the health of the eye surface, and the degree of redness to determine whether the investigational treatment is working better than placebo.

The purpose of the study is to find out whether taking this long-acting nitrate medication by mouth can improve blood circulation to the optic nerve head, which is the part of the nerve at the back of the eye where damage occurs in glaucoma, and whether it can help slow down the progression of the disease when used together with other glaucoma treatments. The study will also examine how the medication affects the structure and function of the eye using various imaging and testing methods.

During the study, participants will attend regular visits where the thickness of the nerve fiber layer at the back of the eye will be measured using a special imaging technique called optical coherence tomography, which uses light waves to take detailed pictures of the eye structures. Visual field testing will also be performed to measure how well participants can see in different areas of their vision. The study will last for 18 months, with measurements taken at the beginning and at 6, 12, and 18 months to track any changes over time. The main focus will be on measuring changes in nerve fiber thickness and visual field measurements to determine whether the medication helps slow down disease progression compared to placebo.